Complexity of gastric acid secretion revealed by targeted gene disruption in mice
- PMID: 20166994
- DOI: 10.2174/138161210790945904
Complexity of gastric acid secretion revealed by targeted gene disruption in mice
Abstract
Physiology of gastric acid secretion is one of the earliest subjects in medical research and education. Gastric acid secretion has been sometimes inadequately expressed as pH value rather than amount of gastric H(+) secreted per unit time. Gastric acid secretion is regulated by endocrine, paracrine and neurocrine signals via at least three messenger pathways: gastrin-histamine, CCK-somatostatin, and neural network. These pathways have been largely validated and further characterized by phenotyping a series of knockout mouse models. The complexity of gastric acid secretion is illustrated by both expected and unexpected phenotypes of altered acid secretion. For examples, in comparison with wild-type mice, gastrin and CCK double knockout and SSTR(2) knockout mice displayed a shift in the regulation of ECL cells from somatostatin-SSTR(2) pathway to galanin-Gal1 receptor pathway; a shift in the regulation of parietal cells from gastrin-histamine pathway to vagal pathway; and a shift in the CCK(2) receptors on parietal cells from functional silence to activation. The biological function of glycine-extended gastrin in synergizing gastrin-17 has been revealed in gastrin knockout mice. The roles of gastric acid secretion in tumorigenesis and ulceration have not been fully understood. Transgenic hypergastrinemic INS-GAS mice developed a spontaneous gastric cancer, which was associated with an impaired acid secretion. Gastrin knockout mice were still able to produce acid in response to vagal stimulation, especially after H. pylori infection. Taken together, phenotyping of a series of genetically engineered mouse models reveals a high degree of complexity of gastric acid secretion in both physiological and pathophysiological conditions.
Similar articles
-
Genetic dissection of the signaling pathways that control gastric acid secretion.Inflammopharmacology. 2005;13(1-3):201-7. doi: 10.1163/156856005774423872. Inflammopharmacology. 2005. PMID: 16259739 Review.
-
Control of gastric acid secretion in somatostatin receptor 2 deficient mice: shift from endocrine/paracrine to neurocrine pathways.Endocrinology. 2008 Feb;149(2):498-505. doi: 10.1210/en.2007-0238. Epub 2007 Nov 1. Endocrinology. 2008. PMID: 17974627 Free PMC article.
-
Chronic Helicobacter pylori infection results in gastric hypoacidity and hypergastrinemia in wild-type mice but vagally induced hypersecretion in gastrin-deficient mice.Regul Pept. 2003 Oct 15;115(3):161-70. doi: 10.1016/s0167-0115(03)00167-8. Regul Pept. 2003. PMID: 14556957
-
Cholecystokinin in the control of gastric acid and plasma gastrin and somatostatin secretion in healthy subjects and duodenal ulcer patients before and after eradication of Helicobacter pylori.J Physiol Pharmacol. 1994 Dec;45(4 Suppl 1):3-66. J Physiol Pharmacol. 1994. PMID: 7787215 Review.
-
Altered control of gastric acid secretion in gastrin-cholecystokinin double mutant mice.Gastroenterology. 2004 Feb;126(2):476-87. doi: 10.1053/j.gastro.2003.11.012. Gastroenterology. 2004. PMID: 14762785
Cited by
-
Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24 h gastric acidity and gastrin in healthy subjects.Br J Clin Pharmacol. 2013 Nov;76(5):680-8. doi: 10.1111/bcp.12095. Br J Clin Pharmacol. 2013. PMID: 23432415 Free PMC article. Clinical Trial.
-
Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects.Br J Clin Pharmacol. 2013 Nov;76(5):689-98. doi: 10.1111/bcp.12099. Br J Clin Pharmacol. 2013. PMID: 23432534 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials